ArticleInfection2024
The high-incidence period of Mycoplasma pneumoniae infections 2023/2024 in southeast Germany was associated with a low level of macrolide resistance.
Article in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China.Clinical and experimental pediatrics · 2026Article
- Coinfection Patterns ofInternational journal of molecular sciences · 2026Article
- Macrolide Resistance and Multilocus Sequence Typing Genotype Analysis ofPublic health weekly report · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Clinical characteristics of hospitalized children with mycoplasma pneumoniae pneumonia in Chinese tertiary hospitals during the 2023-2024 post-pandemic period.Frontiers in cellular and infection microbiology · 2026Article
- Development of a predictive model based on clinical indicators for refractory Mycoplasma pneumoniae pneumonia in children: a case-control study.Frontiers in cellular and infection microbiology · 2026Article
- Prevalence of Macrolide-Resistant Mycoplasma pneumoniae Infections After the COVID-19 Pandemic in Southern Italy, 2023-2025.Infectious diseases and therapy · 2025Article
- Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities.Current opinion in infectious diseases · 2025Review
- Whole genome sequencing confirmed theASM case reports · 2025Article
- Re-emergence of Mycoplasma pneumoniae before and after COVID-19 pandemic in Germany.BMC infectious diseases · 2025Article
- Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA.Emerging infectious diseases · 2025Article
- Mycoplasma pneumoniae MLST detected in the upsurge of pneumonia during the 2023 to 2024 winter season in the Netherlands.Scientific reports · 2025Article
- Biomarkers associated with the diagnosis and prognosis ofFrontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.